Chikungunya Treatment Market size was over USD 1.73 billion in 2023 and is poised to cross USD 3.03 billion by 2036, growing at more than 4.4% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of chikungunya treatment is evaluated at USD 1.79 billion. The growth of the market can be attributed to the growing occurrence of chikungunya, and rise in awareness about mosquito-transmitted infections around the world. According to the World Health Organization, Asia and the Americas were the regions most affected by chikungunya. Pakistan faced a persistent outbreak that started in the year 2017 and reported 8,387 cases, while India suffered with 62,000 cases. Apart from these, ongoing government initiatives regarding prevention control of mosquito breeding, coupled with rising consciousness among people associated with mosquito bites and its consequences, are also expected to be crucial factors driving market growth in the upcoming years. Furthermore, escalating unmet needs for chikungunya diagnosis in the developing and under-developed regions of Asia and Africa, are projected to further the scope of medical examination possibilities for disease control, which in turn is assessed to offer profitable opportunities to the chikungunya treatment market in the near future.
Growth Drivers
Challenges
|
2023 |
|
|
Forecast Year |
2024–2036 |
|
CAGR |
4.4% |
|
Base Year Market Size (2023) |
USD 1.73 billion |
|
Forecast Year Market Size (2036) |
USD 3.03 billion |
|
Regional Scope |
|
The market is segmented by end user into hospitals and clinics, academic institutes, research laboratories, and others, out of which, the hospitals and clinics segment is anticipated to hold the largest share in the chikungunya treatment market. This can be accounted to the large patient pool of chikungunya in hospitals, and high preference of people to be treated in a well-established healthcare facility. In addition, the research laboratories segment is predicted to observe the highest CAGR over the forecast period owing to the increasing number of ongoing researches to develop specific treatment for curing the chikungunya virus. Moreover, on the basis of route of administration, the oral segment is evaluated to occupy the largest share over the forecast period, which can be credited to the cost-effectiveness, non-invasive nature and convenience of taking drugs by this route of dosage.
Our in-depth analysis of the global chikungunya treatment market includes the following segments:
|
By Strain Type |
|
|
By Drug Class |
|
|
By Route of Administration |
|
|
End-User |
|
On the basis of geographical analysis, the chikungunya treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. The market in the Asia Pacific industry is estimated to account for largest revenue share by 2036, driven by growing prevalence of mosquito-transmitted diseases, and rising number of alliances among western market players. Along with these, subsistence of unsanitary conditions in several regions of the Asia is also anticipated to drive APAC’s market growth in the coming years. Additionally, the chikungunya treatment market in North America is expected to acquire the most significant share during the forecast period ascribing to the extensive research and development activities in the healthcare sector, especially in the United States, and presence of well-established healthcare infrastructure in the region. As per the data provided by the Centers for Medicare and Medicaid Services, U.S. health care spending reached USD 3.8 trillion in 2019. As a share of the nation's Gross Domestic Product, health spending accounted for 17.7 percent.
February 2019- Moderna, Inc. initiated the first dose in patients in phase I clinical trial for mRNA-1944, which is an anti-chikungunya antibody for the treatment of chikungunya viral infections.
February 2019- Themis Bioscience received the fast-track designation for MV-CHIK, a vaccine for treating chikungunya viral infections from the United States food and drug administration, FDA.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?